Publikationsserver
Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
The urgent need for vaccines against Ebola virus (EBOV) was underscored by the large outbreak in West Africa (2014–2016). Since then, several promising vaccine candidates have been tested in pre-clinical and clinical studies. As a result, two vaccines were approved for human use in 2019/2020, of...
Gespeichert in:
| Autoren: | , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | 英语 |
| 出版: |
Philipps-Universität Marburg
2023
|
| 主题: | |
| 在线阅读: | PDF-Volltext |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
| 总结: | The urgent need for vaccines against Ebola virus (EBOV) was underscored by the large
outbreak in West Africa (2014–2016). Since then, several promising vaccine candidates have been
tested in pre-clinical and clinical studies. As a result, two vaccines were approved for human use
in 2019/2020, of which one includes a heterologous adenovirus/Modified Vaccinia virus Ankara
(MVA) prime-boost regimen. Here, we tested new vaccine candidates based on the recombinant
MVA vector, encoding the EBOV nucleoprotein (MVA-EBOV-NP) or glycoprotein (MVA-EBOV-GP)
for their efficacy after homologous prime-boost immunization in mice. Our aim was to investigate
the role of each antigen in terms of efficacy and correlates of protection. Sera of mice vaccinated
with MVA-EBOV-GP were virus-neutralizing and MVA-EBOV-NP immunization readily elicited
interferon-
-producing NP-specific CD8+ T cells. While mock-vaccinated mice succumbed to EBOV
infection, all vaccinated mice survived and showed drastically decreased viral loads in sera and
organs. In addition, MVA-EBOV-NP vaccinated mice became susceptible to lethal EBOV infection
after depletion of CD8+ T cells prior to challenge. This study highlights the potential of MVA-based
vaccines to elicit humoral immune responses as well as a strong and protective CD8+ T cell response
and contributes to understanding the possible underlying mechanisms. |
|---|---|
| Item Description: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
| 实物描述: | 23 Seiten |
| DOI: | 10.3390/vaccines10040533 |